RNPA2000

CAS No. 329214-04-2

RNPA2000 ( RNPA 2000 )

Catalog No. M14084 CAS No. 329214-04-2

RNPA2000 is a small-molecule inhibitor of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing (IC50=130 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    RNPA2000
  • Note
    Research use only, not for human use.
  • Brief Description
    RNPA2000 is a small-molecule inhibitor of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing (IC50=130 uM).
  • Description
    RNPA2000 is a small-molecule inhibitor of Staphylococcus aureus RnpA-mediated RNA turnover and tRNA processing (IC50=130 uM); inhibits both RnpA-associated RNA degradation and tRNA maturation activities both in vitro and within S. aureus.
  • Synonyms
    RNPA 2000
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    329214-04-2
  • Formula Weight
    361.42
  • Molecular Formula
    C17H19N3O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N-(2-(2-(4-isopropylphenoxy)acetyl)hydrazine-1-carbonothioyl)furan-2-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Eidem TM, et al. Antimicrob Agents Chemother. 2015 Apr;59(4):2016-28.
2. Lounsbury N, et al. Bioorg Med Chem Lett. 2018 Apr 1;28(6):1127-1131.
molnova catalog
related products
  • VB-82252

    VB-82252 is a highly potent, orally active inhibitor of C. difficile toxins TcdA and TcdB, potently inhibits UDP glucose hydrolysis activity of TcdB (IC50=32 nM).

  • Ceftobiprole medocar...

    Ceftobiprole medocaril is the parenteral prodrug of Ceftobiprole. Ceftobiprole is a broad-spectrum cephalosporin with activity against Methicillin-resistant staphylococcus aureus (MRSA).

  • GSK-729

    A potent, small molecule inhibitor of Mycobacterium tuberculosis enoyl-coenzyme A (CoA) hydratase EchA6 with IC50 of 1.8 uM.